FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing
This article was originally published in The Tan Sheet
Executive Summary
FDA's final rule to reform Hatch/Waxman requires an innovator company to test data to establish that a polymorph claimed in a patent is the same as the active ingredient in the NDA
You may also be interested in...
FDA Questions First-To-File Exclusivity As Generic Reforms Pass Senate
FDA has reservations about the current first-to-file basis for 180-day exclusivity, FDA Chief Counsel Daniel Troy acknowledged at a June 17 Senate Judiciary Committee hearing on generic drug reforms
FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule
Patent declaration forms must be used for Orange Book submission of patent information under FDA's generic reform final rule
FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims
FDA's proposed reforms to the Orange Book patent listing procedures would allow companies to list patents covering polymorphs and some types of manufacturing processes